Pancreatic Cancer Screening in a Population at High Risk

Brief summary public domain (ClinicalTrials.gov)

Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing. In a certain proportion of patients, it is possible to predict the disease, e.g. due to family burdens. Regular follow-up of such individuals is the subject of the SCREPAN study: "Pancreatic Cancer Screening in High-Risk Persons".

Detailed description public domain (ClinicalTrials.gov)

Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the worst prognosis. Mortality in this disease is almost equal to the incidence. In the Czech Republic, the incidence of this cancer has an upward trend, in 2017, 21.2 new cases per 100,000 people were reported, which represents a more than double increase compared to the data from the 1970s. Pancreatic cancer is associated with an extremely poor prognosis for several reasons. It is usually diagnosed at an advanced stage, which is often due to the asymptomatic course of the disease or non-specific symptoms, the lack of sensitive and specific tumor markers, and difficult diagnosis by imaging methods in the early stages. Five-year survival, regardless of clinical stage, is between 7-9%. Resectable disease is diagnosed in only 10% of patients, in which the 5-year survival rate is 37 %, locally advanced unresectable disease is detected in about 30 % of patients with a 5-year survival of 12 %, and metastatic disease is found in about 60 % of patients, with a 5-year survival rate of only around 3 %. The poor prognosis of this disease is also due to the limited possibilities of screening and curative intervention for a short "lead time" in rapidly metastatic disease. Pancreatic cancer screening is not suitable for the non-selected population. On the contrary, it is important for individuals with a high risk of developing this disease. In these subjects, early diagnosis during screening demonstrated a higher number of curative resections and longer survival.

Intervention public domain (ClinicalTrials.gov)

Procedure: endoscopic ultrasonography. endoscopic ultrasonography - frequency defined by arm

Intervention public domain (ClinicalTrials.gov)

Procedure: magnetic resonance. magnetic resonance - frequency defined by arm

Intervention public domain (ClinicalTrials.gov)

Diagnostic_Test: laboratory examination. hematology, biochemistry, Na+, K+, Cl-, Ca2+, bilirubin, ALT, AST, GGT, ALP, lactate dehydrogenase, creatinine, urea, fasting glycemia, HbA1c, alpha-amylase, LPS, albumin, total protein, CA19-9, CEA

Arm public domain (ClinicalTrials.gov)

A - chronic pancreatitis (experimental): Chronic pancreatitis, due to cystic fibrosis

Arm public domain (ClinicalTrials.gov)

B1 - genetic predisposition (STK11, CDKN2A, PRSS1) (experimental): Persons with a confirmed diagnosis of Peutz-Jeghers syndrome (STK11 mutation) or familial melanoma syndrome (CDKN2A mutation), hereditary pancreatitis (PRSS1 mutation)

Arm public domain (ClinicalTrials.gov)

B2 - genetic predisposition of hereditary syndromes (experimental): Persons with a confirmed diagnosis of hereditary syndromes and at the same time with the condition of at least one relative of the first or second degree with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis; i.e. Lynch syndrome (mut: MLH1, MSH2, MSH6 a PMS2, EPCAM), HBOC (mut: BRCA1, BRCA2, PALB2, ATM), familial adenomatous polyposis (mut: APC), Li-Fraumeni syndrome (mut: TP53)

Arm public domain (ClinicalTrials.gov)

C - positive family anamnesis (experimental): Persons with positive family anamnesis of pancreatic ductal adenocarcinoma without proven hereditary syndrome

Primary outcome public domain (ClinicalTrials.gov)

Number of participants with newly diagnosed pancreatic ductal adenocarcinoma. Number of participants (in risk population) with newly diagnosed pancreatic cancer Time frame: From date of subject enrollment annualy in determined examinations according to the protocol schedule until the date of PDAC diagnosis or up to 60 months of subject participation in the study.

Secondary outcome public domain (ClinicalTrials.gov)

Methods yield comparison. Time frame: through study completion, an average of 1 year.

Secondary outcome public domain (ClinicalTrials.gov)

Screening methods cost-effectiveness. Time frame: through study completion, an average of 1 year.

Secondary outcome public domain (ClinicalTrials.gov)

KRAS mutation status evaluation. Time frame: From the date of subject enrollment annualy in determined examinations according to the protocol schedule until the date of PDAC diagnosis or up to 60 months of subject participation in the study.

Eligibility public domain (ClinicalTrials.gov)

Inclusion Criteria: * willing to participate in the study * age 18+ * arms specific criteria: A: * chronic pancreatic disease in the context of cystic fibrosis or chronic pancreatitis * age 50+ B1: * confirmed Peutz-Jegherson syndrome (mutSTK11) + age over 35 years or 10 years earlier than pancreatic ductal adenocarcinoma was diagnosed in the youngest family member * familial melanoma syndrome (mutCDKN2A) + age over 40 years or 10 years before pancreatic ductal adenocarcinoma was diagnosed in the youngest family member * confirmed hereditary pancreatitis (mutPRSS1) + age over 40 years or 20 years after the first attack B2: * confirmed diagnosis of hereditary syndrome (Lynch syndrome /mutMLH1, mutMSH2, mutMSH6, mutPMS2, mutEPCAM/, HBOC /mutBRCA1, mutBRCA2, mutPALB2, mutATM/, familial adenomatous polyposis /mutAPC/, Li-Fraumeni syndrome /mutTP53/) * at least one relative with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis at the same time (Grade I or II relative) * age over 50 years, or 10 years before the pancreatic ductal adenocarcinoma was diagnosed in the youngest relative - which comes first C: * positive family anamnesis of pancreatic ductal adenocarcinoma without hereditary syndrome context * age 50+ or 10 years earlier than the youngest relative with pancreatic ductal adenocarcinoma - screening is recommended for all first-degree relatives of affected family members Exclusion Criteria: * Inability to undergo radical curative surgery for a pancreatic tumor. * Inability to undergo scheduled imaging examinations. * Incurable malignant cancer.

Enrollment public domain (ClinicalTrials.gov)

Enrollment: 700 participants (estimated).